Table 2.

Median overall survival (months) of patients treated with ²²³Ra according to Neutrophil to Lymphocyte ratio (NLR).

	NLR Low (≤5)	NLR High (>5)	HR (95% CI) *	p-Value
baseline	14.5 (10.2–16.4)	8.5 (6.8–10.5)	1.7 (1.00–2.90)	0.05
at 12 weeks	15.0 (12.7–21.4)	9.5 (8.3–18.4)	1.88 (1.07–3.29)	0.03

* Hazard Ratio (HR) adjusted on docetaxel treatment, previous prostatectomy, Eastern Cooperative Group (ECOG) performance status, prostate specific antigen (PSA) level, hemoglobin level (Hb), total alkaline phosphatase (tALP).